$RGNX Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.43 up 131.16% YoY
• Reported revenue of $108.02M up 405.73% YoY
• REGENXBIO expects its balance in cash, cash equivalents, and marketable securities as of June 30, 2026, plus July 2026 proceeds, are sufficient to fund operations for REGENXBIO into Q4 2027.